Pharmafile Logo
Pharmafocus logo
Advanced Search

ankylosing spondylitis

Showing 7 posts of 7 posts found.

gilead-sciences

Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal

September 7, 2018
Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …

News
novartis_iobmr

NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016
Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …

News
AS spine fusion

Novartis’ Cosentyx shows benefits in Phase III AS trials

January 4, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis

Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …

News
Abbvie image

AbbVie highlights treatment adherence

June 12, 2014
Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis

Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …

News
NASS website

Abbott launches online tool for ankylosing spondylitis

April 23, 2012
Medical Communications AS, Abbott, NHS, NICE, ankylosing spondylitis

Abbott has launched a new online assessment tool that has the potential to change the landscape of ankylosing spondylitis (AS) …

News

MSD sways NICE with Simponi patient access scheme

August 26, 2011
Sales and Marketing NICE, Simponi, ankylosing spondylitis

A patient access scheme which lowers Simponi’s cost has led to Merck Sharp and Dohme’s drug being given the thumbs …

News

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis

July 13, 2011
Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab

Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024